Latest News




Jakarta, June 15th, 2022 – The Oncology Division (One Onco) of PT Kalbe Farma Tbk (Kalbe) collaborated with Lovepink (a community of breast cancer patients) in the Free 1000 Breast USG Movement for pre-prosperous women. It was held in several hospitals, including Mitra Keluarga Hospital of Jatiasih, Bekasi, at Wednesday, June 15th, 2022.

“Early detections of breast cancer can save our lifes. Besides SADARI or Breast Self-Examination, we can also conduct SADANIS or Breast Clinical Examination,” according to the President Director and Leader of One Onco, dr. Selvinna.

She stated that 70 percent of breast cancer cases were discovered during the third or higher stages, in which the cancer cells were already spread. Even though SADARI could be easily conducted, not all women could gain access for SADANIS due to their financial limitations.

SADANIS can be conducted during the seventh until the tenth day of the month, starting from the first period, or every same date of the month for women with menopause. If SADARI and SADANIS have been conducted respectively, they can perorm early detections of breast cancer during the first stages, raising the chances of survival for the patients.

Therefore, the Free 1000 Breast USG Movement will hopefully assist more Indonesian women with low incomes to clinically examine their breast health, in order to achieve the dream of Indonesia being free from advanced breast cancers in 2030.

“Kalbe is committed to raise awareness on cancer, especially during early stages, in order to minimalize the risks of its malignancy. We also realize that this action cannot be conducted independently and will require collaborations with many parties,” as dr. Selvinna stated.

“We hope that, with the increasing number of access to breat USG examinations, there will be more women who can clinically detect the cancer, resulting in faster treatments and higher survival rates,” according to the Corporate Director of Branding and Communication Management of Mitra Keluarga, dr. Nurvantina Pandina, M.M.

On the other hand, Lovepink is organizing the Free Breast USG Movement program for pre-prosperous women in Indonesia, which have been initiated since October of 2021. Lovepink has also made collaborations with several hospitals and invited several parties which willingly participate in funding this program.

Lovepink has currently provided access of breast USG examinations for more than 2100 pre-prosperous women, which are still being conducted in Jabodetabek, Yogyakarta, Jember, Padang, Bandung, and Banjarbaru.

As the Vice President of Lovepink, Tri Oetami, stated, “May this program can assist many more Indonesia women with low incomes to clinically examine their breast health, in order to achieve the dream of Indonesia being free from advanced breast cancers in 2030.”

There is also Ultra Pink, a movement initiated by a group of international school students, including from Mentari Intercultural School of Jakarta, Binus School of Simprug, Jakarta International School, British International School, Cita Buana School, and Al Izhar School.

“These students held a virtual charity concert to support the Free 1000 Breast USG Movement from Lovepink. The young generations have a vital role in achieving the dream of Indonesia being free from advanced breast cancers, through encouraging the importance of early detection for breast cancer,” according to a Representative of UltraPink, Fertina Tarasari.

An Instagram Live is also going to be broadcast to increase awareness about the importance of early detection for breast cancer in social media. The discussion will be held on the Instagram accounts of @one.onco, @lovepinkindonesia, and @mitrakeluarga, by presenting several leaders as the speakers and informing about the Free 1000 Breast USG Movement.

For more news about breast cancer, kindly check:

One Onco at a Glance

One Onco is a digital-based ecosystem built by the Oncology Kalbe team, with the purpose of becoming a support system for cancer stakeholders in Indonesia, including cancer warriors, survivors, and caregivers. It provides: 1. Valid and trustworthy updates on information about cancer, 2. Online access for cancer consultation services, 3. Complete and affordable access for early detections of cancer, and 4. Information access regarding health facilities and staff, as well as cancer communities in Indonesia. The One Onco ecosystem has the spirit of technological innovations and collaborations with all relevant health stakeholders, including for cancer, in Indonesia. Other advantages provided by this ecosystem for the society and cancer survivors include:

1.      Helping to increase the literacy and awareness of the society on the correct information about cancer, from early detections to palliative treatments.

2.      Becoming a capable support system for cancer survivors specifically and the society in general.

Kalbe at a Glance

Founded in 1966, PT Kalbe Farma Tbk (Kalbe) is one of the largest open pharmaceutical companies in Southeast Asia. The company has four main divisions that engage in a portfolio of reliable and diversed brands, such as the prescription medicine division, the health product division which handles free medicines, multivitamins, and ready-to-drink supplement beverages, and the distribution and logistics divisions.

Kalbe has also developed a digital service ecosystem for the society, both in B2B with EMOS and in B2C with KlikDokter. EMOS is an order management application system that facilitates the distribution channels in commencing stock management or supply chain, while KlikDokter is a digital platform for health services, specifically telemedicine, which provides necessary health consultations and products for the society.

Now, Kalbe has more than 40 subsidiaries and 15 production facilities with international standards, employing around 16.000 employees who are being stationed in 76 branches all around Indonesia. Kalbe’s shares has been recorded in the Indonesia Stock Exchange (IDX) since 1991 (IDX:KLBF).


729 Rate this article:
No rating

Please login or register to post comments.